Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q1 2025 · 10-Q
Revenue$104.41M$104.41M+10.3% vs Q1 2024 Net Income-$19.59M-$19.59MN/M vs Q1 2024 EPS Diluted-$0.21-$0.21N/M vs Q1 2024 Operating Income-$9,911,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,316,000N/M Margins · derivedOperating margin-9.5%+9.5 pt vs Q1 2024
Net margin-18.8%+2.3 pt vs Q1 2024
ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end